Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608472 | 0.85 | PKM (0.46) | CA2CA1CA12CA9PKM | |
| SCHEMBL20549321 | 0.85 | ALDH1A1 (0.49) | CA2CA1CA12CA9PKM | |
| Hydrochloric Acid SCHEMBL4609743 | 0.83 | PKM (0.45) | CA2CA1CA12CA9PKM | |
| SCHEMBL28301192 | 0.83 | MAPT (0.50) | CA2CA1CA12CA9PKM | |
| SCHEMBL791503 | 0.82 | CA2 (0.50) | CA2CA1CA12CA9PKM | |
| SCHEMBL4609359 | 0.80 | PKM (0.43) | CA2CA1CA12CA9PKM | |
| SCHEMBL2494766 | 0.80 | TRPV4 (0.55) | KDM4EMAPTTDP1ALDH1A1POLB | |
| SCHEMBL7269471 | 0.80 | MAPT (0.46) | KDM4EMAPTTDP1ALDH1A1POLB | |
| SCHEMBL691733 | 0.80 | ALDH1A1 (0.56) | CA2CA1CA12CA9PKM | |
| SCHEMBL1939161 | 0.80 | PDIA6 (0.42) | CA2CA1CA12CA9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0694041-A1 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING N-ALPHA-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-31 | — | — | EP | claimed |
| WO-1994022911-A2 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING Nα-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | claimed |
| EP-4605011-A2 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4370503-A1 | ESTERS OF A RETINOID AND BAKUCHIOL AND PREPARATIONS THEREOF | Conagen Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097746-A1 | ALKENE CYCLOPROPANATION WITH NICKEL CATALYST ENHANCER AND IMPROVED REARRANGEMENT REACTION | CONAGEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024086826-A2 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4337639-A1 | NAMPT INHIBITORS AND USES THEREOF | Remedy Plan, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024050554-A2 | SYNTHESIS OF COTYLENIN AND ANALOGS THEREOF FOR THE DEVELOPMENT OF SELECTIVE MODULATORS OF 14-3-3 PROTEIN-PROTEIN INTERACTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-105753965-A | Conjugate Based Systems For Controlled Drug Delivery | 斯马特塞尔斯公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-105705143-A | Nucleic acid nanostructures for in vivo agent delivery | 达娜-法勃肿瘤研究所公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-105492460-A | Stabilized polypeptide insulin receptor modulators | HARVARD COLLEGE | 2016-04-13 | — | — | CN | disclosed |
| CN-104936595-A | Methods and compositions for locally increasing body fat | TOPOKINE THERAPEUTICS INC | 2015-09-23 | — | — | CN | disclosed |
| CN-104640844-A | Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates-2-formate | DOW AGROSCIENCES LLC | 2015-05-20 | — | — | CN | disclosed |
| CN-103038240-A | Synthetic method for preparing ecteinascidin compounds | PHARMA MAR SA | 2013-04-10 | — | — | CN | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-0694041-A1 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING N-ALPHA-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-31 | — | — | EP | disclosed |
| WO-1994022911-A2 | A PROCESS AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS CONTAINING Nα-METHYLARGININE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | CA2 3446/4885CA1 4098/4885CA12 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.